CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...
DUBLIN – Immatics NV is banking $150 million up front and could earn up to $770 million more in development, regulatory and commercial milestones from a licensing deal with Bristol Myers Squibb Co.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results